Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Z. C. Di Rocco"'
Autor:
Z. C. Di Rocco, Tina Sidoni, Enrico Ricevuto, C. Ficorella, G. Porzio, Barbara Adamo, O. Majorana, P. Pujol, Paolo Marchetti
Publikováno v:
Annals of Oncology. 17:vii5-vii9
Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria
Autor:
Corrado Ficorella, Alessandra Tessitore, G. P. De Rubeis, Enrico Ricevuto, Katia Cannita, T. Ventura, Z. C. Di Rocco, G. Porzio, R. Bisegna, F. De Galitiis, Stefano Martinotti, Paolo Marchetti
Publikováno v:
Annals of Oncology. 14:704-708
Background: Mutations in the p53 gene are the most common genetic alterations in human primary breast carcinoma and these mutations are often associated with worse prognosis and chemo/radioresistance. Patients and methods: The analysis of the p53 gen
Autor:
Corrado Ficorella, Morese R, Enrico Ricevuto, G. Porzio, Z. C. Di Rocco, M. F. Morelli, P. Lanfiuti Baldi, G. Cianci, Katia Cannita
Publikováno v:
British Journal of Cancer
At present, the various mechanisms involved in 5-fluorouracil (5-FU)-correlated cardiotoxicity remain to be elucidated and a universally accepted prophylaxis or treatment for this specific toxicity is not available. Although it may improve time to pr
8591 Background: Little is known about Dicer (D) deregulation in tumour development and/or progression although several recent studies show that a decrease in D expression seems to correlate with s...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::567243fa0b43d29408889d28e7531757
http://hdl.handle.net/11573/913051
http://hdl.handle.net/11573/913051
Autor:
M. F. Morelli, Z. C. Di Rocco, G. Cianci, Corrado Ficorella, Stefano Iacobelli, M. De Tursi, Nicola Tinari, Enrico Ricevuto, Roberto Morese, G. Porzio, Paolo Marchetti, Katia Cannita, F. De Galitiis
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
A dose-finding study was designed to determine the maximum tolerated dose (MTD) of a bimonthly 12-h (10:00 p.m to 10:00 a.m), timed flat infusion (TFI) of 5-fluorouracil (5-FU) plus irinotecan (CPT-11), without leucovorin (LV), for metastatic colorec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e8b69838344a2d112aefed79d78946
http://hdl.handle.net/11573/16150
http://hdl.handle.net/11573/16150
Autor:
Luigi Cavanna, Vittorio Franciosi, L. Verna, Andrea Martoni, M. Ciaparrone, Z. C. Di Rocco, C. Mastromauro, Gabriella Farina, C. Moro, Vittorina Zagonel
Publikováno v:
Annals of Oncology. 23:ix466
Background The early integration of cancer treatment and palliative care (PC) is effective but the current state of integration in Italian Cancer Centers is unknown. Aims To determine the models of integration of PC in Italian Oncology Units ESMO Des